FDA Approval Summary: Capecitabine Labeling Update under Project Renewal
{{output}}
On December 14, 2022, the FDA approved revisions to the United States Prescribing Information (USPI) for capecitabine that revised existing indications and dosage regimens, added new indications and their recommended dosage regimens, revised safety information... ...
